Literature DB >> 29407889

MicroRNA-24 aggravates atherosclerosis by inhibiting selective lipid uptake from HDL cholesterol via the post-transcriptional repression of scavenger receptor class B type I.

Kun Ren1, Xiao Zhu1, Zhi Zheng1, Zhong-Cheng Mo2, Xiao-Shan Peng1, Yong-Zhi Zeng1, Han-Xiao Ou2, Qing-Hai Zhang3, Hui-Zhou Qi1, Guo-Jun Zhao4, Guang-Hui Yi5.   

Abstract

BACKGROUND AND AIMS: Liver scavenger receptor class B type I (SR-BI) exerts atheroprotective effects through selective lipid uptake (SLU) from high-density lipoprotein cholesterol (HDL-C). Low hepatic SR-BI expression leads to high HDL-C levels in the circulation and an increased risk of atherosclerosis. Furthermore, macrophage SR-BI mediates bidirectional cholesterol flux and may protect against atherogenesis. Previous studies have revealed that miR-24 is closely related to cardiovascular disease (CVD) progression. We aimed to investigate the molecular mechanisms by which miR-24 participates in SR-BI-mediated selective HDL cholesteryl ester (HDL-CE) uptake and further atherogenesis in apoE-/- mice.
METHODS: Bioinformatic predictions and luciferase reporter assays were utilized to detect the association between miR-24 and the SR-BI 3' untranslated region (3' UTR), and RT-PCR and western blotting were used to evaluate SR-BI mRNA and protein expression, respectively. The effects of miR-24 on Dil-HDL uptake were determined by flow cytometry assay. Double-radiolabeled HDL (125I-TC-/[3H] CEt-HDL) was utilized to measure the effects of miR-24 on HDL and CE binding and SLU in HepG2 and PMA-treated THP-1 cells. In addition, total cholesterol (TC) levels in HepG2 cells were analyzed using enzymatic methods, and macrophage lipid content was evaluated by high-performance liquid chromatography (HPLC) assay. Small interfering RNA (siRNA) and pcDNA3.1(-)-hSR-BI plasmid transfection procedures were utilized to confirm the role of SR-BI in the effects of miR-24 on Dil-HDL uptake, SLU and cholesterol levels in both cell types. Hepatic SR-BI level in apoE-/- mice was measured by western blotting. Liver TC, FC and CE levels and plasma triglycerides (TG), TC and HDL-C levels were evaluated enzymatically using commercial test kits. Atherosclerotic lesion sizes were measured using Oil Red O and hematoxylin-eosin staining.
RESULTS: miR-24 directly repressed SR-BI expression by targeting its 3'UTR. In addition, miR-24 decreased Dil-HDL uptake and SLU in HepG2 and THP-1 macrophages. In the presence of HDL, miR-24 decreased TC levels in HepG2 cells and TC, free cholesterol (FC) and CE levels in macrophages. Overexpression and down-regulation assays showed that SR-BI mediated the effects of miR-24 on Dil-HDL uptake, SLU and cholesterol levels. Lastly, miR-24 administration decreased hepatic SR-BI expression and promoted atheromatous plaque formation in apoE-/- mice, findings in line with those of our in vitro studies.
CONCLUSIONS: These findings indicate that miR-24 accelerates atherogenesis by repressing SR-BI-mediated SLU from HDL-C.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Atherosclerosis; HDL-Cholesterol; SR-BI; Selective lipid uptake; miR-24

Mesh:

Substances:

Year:  2018        PMID: 29407889     DOI: 10.1016/j.atherosclerosis.2018.01.045

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  17 in total

1.  HDL and microRNAs.

Authors:  Hongtu Cui; Kaixuan Lv; Nana Yang
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

Review 2.  HDL and Scavenger Receptor Class B Type I (SRBI).

Authors:  Hong Yu
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

3.  Silencing METTL3 Stabilizes Atherosclerotic Plaques by Regulating the Phenotypic Transformation of Vascular Smooth Muscle Cells via the miR-375-3p/PDK1 Axis.

Authors:  Jingquan Chen; Kun Lai; Xi Yong; Hongshun Yin; Zhilong Chen; Haifei Wang; Kai Chen; Jianghua Zheng
Journal:  Cardiovasc Drugs Ther       Date:  2022-06-15       Impact factor: 3.727

4.  Protective roles of apremilast via Sirtuin 1 in atherosclerosis.

Authors:  Dongkui Sui; Hua Yu
Journal:  Bioengineered       Date:  2022-05       Impact factor: 6.832

Review 5.  The miR-23-27-24 cluster: an emerging target in NAFLD pathogenesis.

Authors:  Lin Ru; Xiao-Mei Wang; Jun-Qi Niu
Journal:  Acta Pharmacol Sin       Date:  2021-12-10       Impact factor: 7.169

Review 6.  MicroRNAs and obesity-induced endothelial dysfunction: key paradigms in molecular therapy.

Authors:  Karima Ait-Aissa; Quynh My Nguyen; Mohanad Gabani; Adam Kassan; Santosh Kumar; Soo-Kyoung Choi; Alexis A Gonzalez; Tahsin Khataei; Amal M Sahyoun; Cheng Chen; Modar Kassan
Journal:  Cardiovasc Diabetol       Date:  2020-09-09       Impact factor: 9.951

Review 7.  Unravelling HDL-Looking beyond the Cholesterol Surface to the Quality Within.

Authors:  Sarina Kajani; Sean Curley; Fiona C McGillicuddy
Journal:  Int J Mol Sci       Date:  2018-07-06       Impact factor: 5.923

8.  MicroRNA‑24 attenuates diabetic vascular remodeling by suppressing the NLRP3/caspase‑1/IL‑1β signaling pathway.

Authors:  Zhixing Fan; Jian Yang; Chaojun Yang; Jing Zhang; Wanying Cai; Congxin Huang
Journal:  Int J Mol Med       Date:  2020-03-09       Impact factor: 4.101

Review 9.  Non-coding RNAs in cardiovascular cell biology and atherosclerosis.

Authors:  Francesca Fasolo; Karina Di Gregoli; Lars Maegdefessel; Jason L Johnson
Journal:  Cardiovasc Res       Date:  2019-10-01       Impact factor: 10.787

Review 10.  High Density Lipoproteins: Metabolism, Function, and Therapeutic Potential.

Authors:  Anne Jomard; Elena Osto
Journal:  Front Cardiovasc Med       Date:  2020-03-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.